Clinical Features of Children With Relapsed Ph1-negative B-Cell Precursor ALL Enrolled in ALL-REZ-BFM Protocols Tested and Not Tested for TEL-AML1 Expression
| . | TEL-AML1 . | |||
|---|---|---|---|---|
| Not Tested . | Negative . | Positive . | Total . | |
| Gender | ||||
| Boys | 156 | 66 | 22 | 244 |
| Girls | 106 | 35 | 10 | 151 |
| Frontline therapy*,† | ||||
| ALL-BFM | 181 | 81 | 25 | 287 |
| CoALL | 34 | 15 | 4 | 53 |
| NHL-BFM | 5 | 2 | 0 | 7 |
| Others | 42 | 3 | 3 | 48 |
| Relapse | ||||
| First | 227 | 89 | 27 | 343 |
| Second | 35 | 12 | 5 | 52 |
| Time point*,‡ | ||||
| Very early | 54 | 28 | 2 | 84 |
| Early | 82 | 33 | 4 | 119 |
| Late | 126 | 40 | 26 | 192 |
| Site | ||||
| BM isolated | 185 | 67 | 19 | 271 |
| BM combined | 55 | 23 | 10 | 88 |
| Extramedullary | 22 | 11 | 3 | 36 |
| Therapy group | ||||
| S1 | 5 | 4 | 3 | 12 |
| S2 | 159 | 51 | 21 | 231 |
| S3 | 49 | 18 | 5 | 72 |
| S4 | 49 | 28 | 3 | 80 |
| Response to therapy | ||||
| Remission achieved | 224 | 82 | 30 | 336 |
| Progressive disease | 25 | 10 | 1 | 36 |
| Death during induction | 13 | 9 | 1 | 23 |
| Total | 262 | 101 | 32 | 395 |
| BMT1-153 | ||||
| None | 156 | 60 | 23 | 239 |
| Allogeneic | 46 | 19 | 7 | 72 |
| Autologous | 22 | 3 | 0 | 25 |
| Events in remission*,1-155 | ||||
| None | 106 | 53 | 25 | 184 |
| Second malignancy | 1 | 0 | 0 | 1 |
| Relapse | 67 | 16 | 1 | 84 |
| Lapse after BMT | 31 | 7 | 2 | 40 |
| Chemotherapy-related death | 11 | 2 | 1 | 14 |
| BMT-related death | 8 | 4 | 1 | 13 |
| Total | 224 | 82 | 30 | 336 |
| . | TEL-AML1 . | |||
|---|---|---|---|---|
| Not Tested . | Negative . | Positive . | Total . | |
| Gender | ||||
| Boys | 156 | 66 | 22 | 244 |
| Girls | 106 | 35 | 10 | 151 |
| Frontline therapy*,† | ||||
| ALL-BFM | 181 | 81 | 25 | 287 |
| CoALL | 34 | 15 | 4 | 53 |
| NHL-BFM | 5 | 2 | 0 | 7 |
| Others | 42 | 3 | 3 | 48 |
| Relapse | ||||
| First | 227 | 89 | 27 | 343 |
| Second | 35 | 12 | 5 | 52 |
| Time point*,‡ | ||||
| Very early | 54 | 28 | 2 | 84 |
| Early | 82 | 33 | 4 | 119 |
| Late | 126 | 40 | 26 | 192 |
| Site | ||||
| BM isolated | 185 | 67 | 19 | 271 |
| BM combined | 55 | 23 | 10 | 88 |
| Extramedullary | 22 | 11 | 3 | 36 |
| Therapy group | ||||
| S1 | 5 | 4 | 3 | 12 |
| S2 | 159 | 51 | 21 | 231 |
| S3 | 49 | 18 | 5 | 72 |
| S4 | 49 | 28 | 3 | 80 |
| Response to therapy | ||||
| Remission achieved | 224 | 82 | 30 | 336 |
| Progressive disease | 25 | 10 | 1 | 36 |
| Death during induction | 13 | 9 | 1 | 23 |
| Total | 262 | 101 | 32 | 395 |
| BMT1-153 | ||||
| None | 156 | 60 | 23 | 239 |
| Allogeneic | 46 | 19 | 7 | 72 |
| Autologous | 22 | 3 | 0 | 25 |
| Events in remission*,1-155 | ||||
| None | 106 | 53 | 25 | 184 |
| Second malignancy | 1 | 0 | 0 | 1 |
| Relapse | 67 | 16 | 1 | 84 |
| Lapse after BMT | 31 | 7 | 2 | 40 |
| Chemotherapy-related death | 11 | 2 | 1 | 14 |
| BMT-related death | 8 | 4 | 1 | 13 |
| Total | 224 | 82 | 30 | 336 |
Abbreviation: NHL, non-Hodgkin's lymphoma.
Not independently distributed as assessed by Fischer's exact test (2-tailed).
Across tested and not tested, P = .00510.
Among TEL-AML1–positive and –negative, P = .000188.
Only children in complete remission were eligible for BMT.
Across tested and not tested, P = .00260.